TY - JOUR
T1 - Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1
T2 - a global approach
AU - Nalca, Yusuf
AU - Jänsch, Lothar
AU - Bredenbruch, Florian
AU - Geffers, Robert
AU - Buer, Jan
AU - Häussler, Susanne
PY - 2006/5
Y1 - 2006/5
N2 - The administration of macrolides such as azithromycin for chronic pulmonary infection of cystic fibrosis patients has been reported to be of benefit. Although the mechanisms of action remain obscure, anti-inflammatory effects as well as interference of the macrolide with Pseudomonas aeruginosa virulence factor production have been suggested to contribute to an improved clinical outcome. In this study we used a systematic approach and analyzed the impact of azithromycin on the global transcriptional pattern and the protein expression profile of P. aeruginosa PAO1 cultures versus those in untreated controls. The most remarkable result of this study is the finding that azithromycin exhibited extensive quorum-sensing antagonistic activities. In accordance with the inhibition of the quorum-sensing systems, virulence factor production was diminished and the oxidative stress response was impaired, whereas the type III secretion system was strongly induced. Moreover, P. aeruginosa motility was reduced, which probably accounts for the previously observed impaired biofilm formation capabilities of azithromycin-treated cultures. The interference of azithromycin with quorum-sensing-dependent virulence factor production, biofilm formation, and oxidative stress resistance in P. aeruginosa holds great promise for macrolide therapy in cystic fibrosis. Clearly quorum-sensing antagonist macrolides should be paid more attention in the management of chronic P. aeruginosa infections, and as quorum-sensing antagonists, macrolides might gain vital importance for more general application against chronic infections.
AB - The administration of macrolides such as azithromycin for chronic pulmonary infection of cystic fibrosis patients has been reported to be of benefit. Although the mechanisms of action remain obscure, anti-inflammatory effects as well as interference of the macrolide with Pseudomonas aeruginosa virulence factor production have been suggested to contribute to an improved clinical outcome. In this study we used a systematic approach and analyzed the impact of azithromycin on the global transcriptional pattern and the protein expression profile of P. aeruginosa PAO1 cultures versus those in untreated controls. The most remarkable result of this study is the finding that azithromycin exhibited extensive quorum-sensing antagonistic activities. In accordance with the inhibition of the quorum-sensing systems, virulence factor production was diminished and the oxidative stress response was impaired, whereas the type III secretion system was strongly induced. Moreover, P. aeruginosa motility was reduced, which probably accounts for the previously observed impaired biofilm formation capabilities of azithromycin-treated cultures. The interference of azithromycin with quorum-sensing-dependent virulence factor production, biofilm formation, and oxidative stress resistance in P. aeruginosa holds great promise for macrolide therapy in cystic fibrosis. Clearly quorum-sensing antagonist macrolides should be paid more attention in the management of chronic P. aeruginosa infections, and as quorum-sensing antagonists, macrolides might gain vital importance for more general application against chronic infections.
KW - Anti-Bacterial Agents/pharmacology
KW - Azithromycin/pharmacology
KW - Gene Expression Profiling
KW - Gene Expression Regulation, Bacterial/drug effects
KW - Genes, Bacterial
KW - Hydrogen Peroxide/pharmacology
KW - Mass Spectrometry
KW - Oxidants/pharmacology
KW - Peptide Mapping
KW - Protein Array Analysis
KW - Proteome
KW - Pseudomonas aeruginosa/drug effects
KW - Transcription, Genetic
KW - Virulence
U2 - 10.1128/AAC.50.5.1680-1688.2006
DO - 10.1128/AAC.50.5.1680-1688.2006
M3 - Journal article
C2 - 16641435
SN - 0066-4804
VL - 50
SP - 1680
EP - 1688
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 5
ER -